Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics
Checkpoint Therapeutics, Inc. (CKPT)
Today's Latest Price: $2.81 USD
Updated Sep 25 4:00pm
Add CKPT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 233 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CKPT Stock Summary
- For CKPT, its debt to operating expenses ratio is greater than that reported by merely 0.34% of US equities we're observing.
- CKPT's price/sales ratio is 127.91; that's higher than the P/S ratio of 97.66% of US stocks.
- As for revenue growth, note that CKPT's revenue has grown -70.29% over the past 12 months; that beats the revenue growth of only 2.17% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Checkpoint Therapeutics Inc are SYRS, LPTX, BBIO, GLYC, and SURF.
- CKPT's SEC filings can be seen here. And to visit Checkpoint Therapeutics Inc's official web site, go to www.checkpointtx.com.
CKPT Stock Price Chart Technical Analysis Charts
CKPT Price/Volume Stats
| Current price | $2.81 | 52-week high | $4.50 |
| Prev. close | $2.74 | 52-week low | $1.05 |
| Day low | $2.68 | Volume | 732,791 |
| Day high | $2.85 | Avg. volume | 598,556 |
| 50-day MA | $2.52 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 168.71M |
Checkpoint Therapeutics, Inc. (CKPT) Company Bio
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Loading social stream, please wait...